PDF(Pubmed)
Abstract：
In spite of the great progress in the management of critical diseases in recent years, its associated prevalence and mortality of multiple organ failure still remain high. As an endocrine hormone, fibroblast growth factor 21 (FGF21) functions to maintain homeostasis in the whole body. Recent studies have proved that FGF21 has promising potential effects in critical diseases. FGF21 has also been found to have a close relationship with the progression of critical diseases and has a great predictive function for organ failure. The level of FGF21 was elevated in both mouse models and human patients with sepsis or other critical illnesses. Moreover, it is a promising biomarker and has certain therapeutic roles in some critical diseases. We focus on the emerging roles of FGF21 and its potential effects in critical diseases including acute lung injury/acute respiratory distress syndrome (ALI/ARDS), acute myocardial injury (AMI), acute kidney injury (AKI), sepsis, and liver failure in this review. FGF21 has high application value and is worth further studying. Focusing on FGF21 may provide a new perspective for the management of the critical diseases.
摘要：
尽管近年来在危重疾病的管理方面取得了很大进展，其相关的多器官功能衰竭的患病率和死亡率仍然很高。作为一种内分泌激素,成纤维细胞生长因子21（FGF21）的功能是维持全身的体内平衡。最近的研究证明，FGF21在危重疾病中具有潜在的潜在作用。FGF21也被发现与危重疾病的进展密切相关,并且对器官衰竭具有很大的预测功能。FGF21的水平在患有脓毒症或其他严重疾病的小鼠模型和人类患者中均升高。此外，它是一种很有前途的生物标志物，在一些重大疾病中具有一定的治疗作用。我们专注于FGF21的新兴作用及其在包括急性肺损伤/急性呼吸窘迫综合征（ALI/ARDS）在内的危重疾病中的潜在作用。急性心肌损伤(AMI),急性肾损伤(AKI),脓毒症,和肝衰竭在这篇综述中。FGF21具有较高的应用价值，值得进一步研讨。关注FGF21可能为危重疾病的管理提供新的视角。
